First-in-human study of FAZ053, an anti-PD-L1 mAb, alone and in combination with spartalizumab, an anti-PD-1 mAb, in patients with advanced malignancies Meeting Abstract
| Authors: | Janku, F.; Tan, D.; Martin-Liberal, J.; Takahashi, S.; Geva, R.; Gucalp, A.; Chen, X.; Subramanian, K.; Mataraza, J.; Wheler, J.; Bedard, P. |
| Abstract Title: | First-in-human study of FAZ053, an anti-PD-L1 mAb, alone and in combination with spartalizumab, an anti-PD-1 mAb, in patients with advanced malignancies |
| Meeting Title: | 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 6 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Nov 7-11 |
| Meeting Location: | Washington, DC |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2018-11-06 |
| Start Page: | 115 |
| Language: | English |
| PMCID: | PMC6220479 |
| PUBMED: | 30400822 |
| DOI: | 10.1186/s40425-018-0423-x |
| PROVIDER: | manual |
| Notes: | Meeting Abstract: P651 -- Erratum issued, see DOI: 10.1186/s40425-019-0519-y |
